Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

Overview

Journal Int J Mol Imaging

Date 2012 Oct 11

PMID 23050139

Citations 34

Authors

Steven G Dubois

Ethan Geier

Vandana Batra

Sook Wah Yee

John Neuhaus

Mark Segal

Daniel Martinez

Bruce Pawel

Greg Yanik

Arlene Naranjo

Wendy B London

Susan Kreissman

David Baker

Edward Attiyeh

Michael D Hogarty

John M Maris

Kathleen Giacomini

Katherine K Matthay

Affiliations

Soon will be listed here.

Abstract

Purpose. (123)I-metaiodobenzylguanidine (MIBG) is used for the diagnostic evaluation of neuroblastoma. We evaluated the relationship between norepinephrine transporter (NET) expression and clinical MIBG uptake. Methods. Quantitative reverse transcription PCR (N = 82) and immunohistochemistry (IHC; N = 61) were performed for neuroblastoma NET mRNA and protein expression and correlated with MIBG avidity on diagnostic scans. The correlation of NET expression with clinical features was also performed. Results. Median NET mRNA expression level for the 19 MIBG avid patients was 12.9% (range 1.6-73.7%) versus 5.9% (range 0.6-110.0%) for the 8 nonavid patients (P = 0.31). Median percent NET protein expression was 50% (range 0-100%) in MIBG avid patients compared to 10% (range 0-80%) in nonavid patients (P = 0.027). MYCN amplified tumors had lower NET protein expression compared to nonamplified tumors (10% versus 50%; P = 0.0002). Conclusions. NET protein expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression.

Citing Articles

Substrate binding and inhibition mechanism of norepinephrine transporter.

Ji W, Miao A, Liang K, Liu J, Qi Y, Zhou Y Nature. 2024; 633(8029):473-479.

PMID: 39143211 DOI: 10.1038/s41586-024-07810-5.

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.

Kumar P, Koach J, Nekritz E, Mukherjee S, Braun B, Dubois S EJNMMI Res. 2024; 14(1):54.

PMID: 38869684 PMC: 11176152. DOI: 10.1186/s13550-024-01112-7.

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to I-MIBG in patients with relapsed/refractory neuroblastoma.

Batra V, Gikandi A, Pawel B, Martinez D, Granger M, Marachelian A Pediatr Blood Cancer. 2023; 71(1):e30743.

PMID: 37885116 PMC: 10842219. DOI: 10.1002/pbc.30743.

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.

Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.

PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.

The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.

Vieira L, Zhang Y, Quinones A, Hu T, Singh D, Stevens J J Pharmacol Exp Ther. 2023; 387(3):239-248.

PMID: 37541765 PMC: 10658915. DOI: 10.1124/jpet.123.001672.

References

Taggart D, Dubois S, Matthay K . Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008; 52(4):403-18. View

Fullerton N, Mairs R, Kirk D, Keith W, Carruthers R, McCluskey A . Application of targeted radiotherapy/gene therapy to bladder cancer cell lines. Eur Urol. 2005; 47(2):250-6. DOI: 10.1016/j.eururo.2004.09.009. View

Binderup T, Knigge U, Mogensen A, Hansen C, Kjaer A . Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008; 87(4):223-32. DOI: 10.1159/000113128. View

Dubois S, Matthay K . Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008; 35 Suppl 1:S35-48. PMC: 2633223. DOI: 10.1016/j.nucmedbio.2008.05.002. View

Boyd M, Cunningham S, Brown M, Mairs R, Wheldon T . Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther. 1999; 6(6):1147-52. DOI: 10.1038/sj.gt.3300905. View

Doubrovin M, Doubrovina E, Zanzonico P, Sadelain M, Larson S, OReilly R . In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Res. 2007; 67(24):11959-69. DOI: 10.1158/0008-5472.CAN-07-1250. View

Carlin S, Mairs R, McCluskey A, Tweddle D, Sprigg A, Estlin C . Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003; 9(9):3338-44. View

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt T, Kreft A . 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine.... J Clin Endocrinol Metab. 2010; 95(6):2800-10. DOI: 10.1210/jc.2009-2352. View

Matthay K, Yanik G, Messina J, Quach A, Huberty J, Cheng S . Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007; 25(9):1054-60. DOI: 10.1200/JCO.2006.09.3484. View

10.

Lode H, Bruchelt G, Seitz G, Gebhardt S, Gekeler V, Niethammer D . Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer. 1995; 31A(4):586-90. DOI: 10.1016/0959-8049(95)00039-l. View

11.

Mairs R, Livingstone A, Gaze M, Wheldon T, Barrett A . Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994; 70(1):97-101. PMC: 2033329. DOI: 10.1038/bjc.1994.256. View

12.

Bayer M, Kuci Z, Schomig E, Grundemann D, Dittmann H, Handgretinger R . Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nucl Med Biol. 2009; 36(3):287-94. DOI: 10.1016/j.nucmedbio.2008.12.010. View

13.

More S, Itsara M, Yang X, Geier E, Tadano M, Seo Y . Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011; 17(8):2339-49. PMC: 3247296. DOI: 10.1158/1078-0432.CCR-10-2949. View

14.

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

15.

Montaldo P, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M . Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer. 1996; 67(1):95-100. DOI: 10.1002/(SICI)1097-0215(19960703)67:1<95::AID-IJC16>3.0.CO;2-B. View

16.

Brans B, Laureys G, Schelfhout V, Wiele C, Potter C, Dhooge C . Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. Eur J Nucl Med. 1998; 25(2):144-9. DOI: 10.1007/s002590050207. View

17.

Fullerton N, Boyd M, Mairs R, Keith W, Alderwish O, Brown M . Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer Prostatic Dis. 2004; 7(4):355-63. DOI: 10.1038/sj.pcan.4500760. View

18.

Cunningham S, Boyd M, Brown M, Carlin S, McCluskey A, Livingstone A . A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol. 2000; 35(6):708-11. DOI: 10.1002/1096-911x(20001201)35:6<708::aid-mpo49>3.0.co;2-f. View

19.

Kolby L, Bernhardt P, Levin-Jakobsen A, Johanson V, Wangberg B, Ahlman H . Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer. 2003; 89(7):1383-8. PMC: 2394326. DOI: 10.1038/sj.bjc.6601276. View

20.

Altmann A, Kissel M, Zitzmann S, Kubler W, Mahmut M, Peschke P . Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med. 2003; 44(6):973-80. View